APA

Van Maerken T., Ferdinande L., Taildeman J., Lambertz I., Yigit N., Vercruysse L., Rihani A., Michaelis M., Cinatl J., Cuvelier C. A., Marine J., De Paepe A., Bracke M., Speleman F. & Vandesompele J. (20091202). Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. : Journal of the National Cancer Institute.

Chicago

Van Maerken Tom, Ferdinande Liesbeth, Taildeman Jasmien, Lambertz Irina, Yigit Nurten, Vercruysse Liesbeth, Rihani Ali, Michaelis Martin, Cinatl Jindrich, Cuvelier Claude A, Marine Jean-Christophe, De Paepe Anne, Bracke Marc, Speleman Frank and Vandesompele Jo. 20091202. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. : Journal of the National Cancer Institute.

Harvard

Van Maerken T., Ferdinande L., Taildeman J., Lambertz I., Yigit N., Vercruysse L., Rihani A., Michaelis M., Cinatl J., Cuvelier C. A., Marine J., De Paepe A., Bracke M., Speleman F. and Vandesompele J. (20091202). Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. : Journal of the National Cancer Institute.

MLA

Van Maerken Tom, Ferdinande Liesbeth, Taildeman Jasmien, Lambertz Irina, Yigit Nurten, Vercruysse Liesbeth, Rihani Ali, Michaelis Martin, Cinatl Jindrich, Cuvelier Claude A, Marine Jean-Christophe, De Paepe Anne, Bracke Marc, Speleman Frank and Vandesompele Jo. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. : Journal of the National Cancer Institute. 20091202.